Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App





Nova Biomedical Demonstrates Whole Blood Critical and POC Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021

Nova Biomedical (Waltham, MA, USA) demonstrated its whole blood critical and POC testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30. More...

The event provided an unparalleled opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology & vital research in the field.

Nova is a world leader in whole blood critical and POC testing, offering hospital meters (including StatStrip Glucose, the only FDA-cleared meter for critically ill testing) and Stat Profile Prime critical care blood gas analyzers. At AACC 2021, Nova demonstrated its Stat Profile Prime Plus - a comprehensive, whole blood critical care analyzer that offers blood gases, electrolytes, metabolites, hematology, and co-oximetry, in a simple, compact device. Prime Plus combines maintenance-free, replaceable cartridge technology for sensors and reagents with patented, maintenance-free, and non-lysing whole blood co-oximetry technology. The analyzer uses a small 135µL sample, produces a complete 22-test panel in about one minute, and offers automated quality control with real-time, supplement quality monitoring of each sample analysis, calibration, and QC analysis. Prime Plus is the only critical care analyzer that includes BUN, creatinine, ionized magnesium, estimated plasma volume, and MCHC in its test menu. The complete test menu includes pH, PCO2, PO2, Na, K, Cl, iCa, iMg, Glucose, Lactate, BUN/Urea, Creatinine, Hct, Hb, estimated Plasma Volume, MCHC, SO2%, and CO-Oximetry.

At AACC 2021, Nova also displayed the StatStrip Glucose Hospital Meter, which is the only glucose meter cleared by the FDA for use with critically ill patients and CLIA-waived for use with ALL patients and ALL sample types. StatStrip Glucose has no known interferences and brings lab-like accuracy to bedside glucose testing - accuracy validated in an FDA submission study of 1,698 critically ill patients with 257 different and specific medical conditions, and over 8,000 medications, as well as over 200 published studies worldwide. StatStrip Glucose measures glucose and corrects for hematocrit, maltose, and other interferences that can cause erroneous results on other meters.

Related Links:
Nova Biomedical 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Automated Clinical Chemistry Analyzer
Envoy 500+
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.